5693-25-4

Upstream product

• 152361-07-4 2,2-Diphenyl-1,3-benzodioxolane-5-carboxylic acid, ethyl ester 
• 2051-90-3 Dichlorodiphenylmethane 
• 3943-89-3 Ethyl protocatechuate 
• 99-50-3 3,4-Dihydroxybenzoic acid 

Downstream Products

• 152361-08-5 2,2-Diphenyl-1,3-benzodioxolane-5-carbonyl chloride 
• 152360-09-3 Ethyl 4-[3-(3,4-dihydroxybenzoyl)indol-1-yl]butanoate 
• 152360-60-6 3-[(2,2-diphenyl-1,3-benzodioxolan-5-yl)carbonyl]indole 
• 152360-11-7 ethyl 4-[3-([2,2-diphenyl-1,3-benzodioxolan-5-yl]carbonyl)indol-1-yl]butanoate 
• 1260095-63-3 4-(2,2-diphenylbenzo[d][1,3]dioxole-5-carboxamido)-N₁,N₇-bis(3-methoxymethylphenyl)-4-(3-(3-methoxymethylphenylamino)-3-oxopropyl)heptanediamide 
• 1260095-64-4 4-(2,2-diphenylbenzo[d][1,3]dioxole-5-carboxamido)-N₁,N₇-bis(3,5-bis(methoxymethyl)phenyl)-4-(3-(3,5-bis(methoxymethyl)phenylamino)-3-oxopropyl)heptanediamide 
• 1260095-62-2 N-(3,5-bis(methoxymethyl)phenyl)-2,2-diphenylbenzo[d][1,3]dioxole-5-carboxamide 
• 1260095-61-1 N-(3-methoxymethylphenyl)-2,2-diphenylbenzo[d][1,3]dioxole-5-carboxamide 

Relevant academic research and scientific papers

Design, synthesis and evaluation of phenylfuroxan nitric oxide-donor phenols as potential anti-diabetic agents

Both nitric oxide (NO) dysfunction and oxidative stress have been regarded as the important factors in the development and progression of diabetes and its complications. Multifunctional compounds with hypoglycemic, NO supplementation and anti-oxidation will be the promising agents for treatment of diabetes. In this study, six phenylfuroxan nitric oxide (NO) donor phenols were synthesized, which were designed via a combination approach with phenylfuroxan NO-donor and natural phenols. These novel synthetic compounds were screened in vitro for α-glucosidase inhibition, NO releasing, anti-oxidation, anti-glycation and anti-platelet aggregation activity as well as vasodilatation effects. The results exhibited that compound T5 displayed more excellent activity than other compounds. Moreover, T5 demonstrated significant hypoglycemic activity in diabetic mice and oral glucose tolerance test (OGTT) mice. T5 also showed NO releasing and anti-oxidation in diabetic mice. Based on these results, compound T5 deserves further study as potential new multifunctional anti-diabetic agent with antioxidant, NO releasing, anti-platelet aggregation and vasodilatation properties.

Phenylsulfonylfuroxan NO-donor phenols: Synthesis and multifunctional activities evaluation

Phenylsulfonyfuroxan nitric oxide (NO)-donor phenols were designed, synthesized and evaluated. The compounds were designed through a symbiotic approach using selected phenols and phenylsulfonylfuroxan NO-donor. The antioxidant activities of the hybrid compounds T2–T6 showed to be good in vivo. Compounds T4 and T6 revealed excellent yeast α-glucosidase inhibitory activity and anti-glycosylation activity. All of the compounds exhibited strong NO releasing activity and significant anti-platelet aggregation activity. The inhibition of platelet aggregation was more than 50% at low concentration (1.5?μM) and 95% at higher concentration (15?μM and 150?μM). The vasodilatation experiment demonstrated that the six compounds under test exhibited definite vasodilation activity (pIC50 ranged from 5.698 to 6.383), especially compound T6 (pIC50 was 6.383) which was similar to sodium nitroprusside (pIC50 was 6.786). Both anticoagulant and vasodilatation effects were correlated with their NO releasing activities. These hybrid phenylsulfonyfuroxan-based NO-donor phenols offer a multifunctional prodrug design concept for the development of therapeutic or preventive agents for metabolic syndrome.

Indoles which have steroid 5-α reductase inhibitory activity

The present invention provides compounds of the formula: STR1 and the pharmaceutically acceptable salts thereof, together with pharmaceutically compositions containing, uses of, processes for the preparation of and intermediates used in the preparation of, such compounds.

The development of non-steroidal dual inhibitors of both human 5α- reductase isozymes

The design, synthesis and biological properties of homochiral non- steroidal inhibitors of both isozymes of human 5α-reductase are described. The o-hydroxy aniline moiety of the initial lead (1) can be replaced by a 3- acyl indole isostere, whilst the minimum energy conformation of the benzyl ether in the potent inhibitor (3) is mimicked by the conformationally locked benzodioxolane system in the potent non-steroidal inhibitor (7). Pharmacokinetics and oral efficacy in a rat model of BPH are presented for (3) and (7).